Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers • Medical Oncology • Internal Medicine • Hematology • Nuclear Medicine
Do you give Ra-223 (Xofigo) to patients diagnosed as having benign neutropenia (ANC 1.0-1.5) who are otherwise eligible to receive this radioisotope?
If patients can receive chemotherapy with an ANC of 1-1.5, should they be eligible to receive Ra-223 and other radiopharmaceuticals? What other factors do you consider?